Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Can-Fite BioPharma has completed a Phase I clinical trial with its second pipeline drug, CF102.
Subscribe to our email newsletter
The trial successfully met its objectives of evaluating the safety profile and pharmacokinetic of CF102 single doses, and of determining a dose range for future clinical studies. CF102 was very well-tolerated, with no severe adverse events seen and no dose-limiting toxicity observed. The half-life time of CF102 supports once- or twice-daily dosing and exposure levels are above those expected to have pharmacologic activity in hepatitis C (HCV) and hepatocellular carcinoma (HCC).
Can-Fite is developing CF102 for the treatment of liver disease including HCC and HCV. The trial was a first exposure in humans and was conducted in the US under an IND in 25 healthy volunteers who were given the drug at one of five escalating doses.
Can-Fite currently intends to develop CF102 for the treatment of liver diseases including HCC and HCV. CF102, which was developed, based on Can-Fite’s technology platform is a targeted drug with high affinity and selectivity to the A3 adenosine receptor.